Notification of Results

ABCAM PLC

("Abcam" or "the Company")

Notification of Preliminary Results

Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, will announce its preliminary results for the 12 months ended 30 June 2010 on Tuesday 7 September 2010.

An analyst meeting will be held at 10:30am on Tuesday 7 September at the offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE.

For further information please contact:

Abcam + 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Jeff Iliffe, Chief Financial Officer

www.abcam.com

Numis Securities + 44 (0) 20 7260 1000

Michael Meade / Nick Westlake - Nominated Adviser

James Black - Corporate Broking

Buchanan Communications + 44 (0) 20 7466 5000

Mark Court

Notes for editors

About Abcam plc

Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with subsidiaries in Cambridge, Massachusetts, Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies and related products to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name. Abcam's mission is to develop the largest catalogue of the best antibodies in the world, with the vision of becoming a global leader in the wider protein detection and regulation markets. Abcam now has a rapidly growing online catalogue and as at 30 June 2010 it contained 63,000 products, most of which are antibodies, from over 250 suppliers. Abcam employs 270 staff in its four operating companies.